Rare complications

Changes of ECG parameters after BNT162b2 vaccine in the senior high school students https://pubmed.ncbi.nlm.nih.gov/36602621/ Full text link https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813456/ Data collected, December 2021 Published, January 2023 Aims Determine the ECG parameter change Determine efficacy of ECG screening after the second dose of BNT162b2 In cooperation with the school vaccination system of Taipei City government (Taiwan) N = 4,928 (mostly male) 12 to 18 year old Before and after 12 lead ECGs Three follow up 12 lead ECGs ECGs read by by pediatric cardiologists Serial comparisons of ECGs and questionnaire survey Heart rate increased significantly after the vaccine, (mean increase of 2.6 beats per minute) QRS duration and QT interval decreased significantly after the vaccine with increasing heart rate 763 (17.1%) had at least one cardiac symptom after the second vaccine dose. After the first dose, 209 (5.7%) had at least one cardiac symptom Cardiac symptoms Chest pain Palpitations Dizziness or syncope Depolarization and repolarization parameters All 4 cardiac symptoms significantly higher after the second dose of BNT162b2 vaccine (p less than 0.001) N = 4,928 Abnormal ECGs were obtained in 51 (1.0%) 31 students were asymptomatic ST – T changes, 37 Premature ventricular contractions, 4 Sinus bradycardia, 2 Atrial tachycardia, 1 Incomplete right bundle branch block, 3 Abnormal QRS, 2 Prolonged QT, 2 4 judged to have significant arrhythmia 1 was diagnosed with mild myocarditis 10, suspected pericarditis All of these symptoms improved over time Asymptomatic at one month No covid in Taiwan at this time. Conclusion Cardiac symptoms are common after the second dose of BNT162b2 vaccine Incidences of significant arrhythmias and myocarditis are 0.1% One in a thousand Rotavirus vaccine Rotashield, (1999) https://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-rotashield-historical.htm 1 to 2 serious events per 10,000 vaccinees (Intussusception) Vaccine withdrawn From the authors BNT162b2 has a better safety profile than mRNA-1273 Moderna Cardiac-related adverse effects, as peri- and myocarditis, are of particular concern because of possible serious complications US vaccina advice https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html#children https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html CDC recommends one updated (bivalent) booster dose: • For everyone aged 5 years and older if it has been at least 2 months since your last dose. • For children aged 6 months–4 years who completed the Moderna primary series and if it has been at least 2 months since their last dose. UK vaccine advice Who can get a COVID-19 vaccine Everyone aged 5 (on or before 31 August 2022) and over can get a 1st and 2nd dose of the COVID-19 vaccine. People aged 16 and over, and some children aged 12 to 15, can also get a booster dose.